findmyKOL

Mark Hall

Basic profile

Rheumatology

ORCIDNone on fileNPI
RegionWestlake Village, CA · WestSpecialtyRheumatologyFocusRheumatology/Immunology
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPaymentsNone reportedNIH fundingNot yet indexedWhy? →

Mark Hall is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

141 Triunfo Canyon Rd Ste 110
Westlake Village, CA 913612525

Telephone

805-371-1393

Provider last certified this registry record 16 Nov 2020.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    82.4%
    RANK Ligand Inhibitor76.9%
    Denosumab100%
    Part B, office-administered16 patients
    Xanthine oxidase inhibitor4.5%
    Allopurinol100%
    Part D21 patients

    + 1 more class in this area

  • Cancer & immunology

    8%
    Folate Analog Metabolic Inhibitor2.6%
    Methotrexate100%
    Part D<11 patients
    TNF inhibitor2.5%
    Enbrel Sureclick58%Humira(Cf) Pen42%
    Part D<11 patients

    + 3 more classes in this area

  • Metabolism & gastrointestinal

    6.5%
    Corticosteroid4.5%
    Prednisone100%
    Part D32 patients
    Aminosalicylate2%
    Sulfasalazine Dr100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”